Cost per responder analysis of abrocitinib versus dupilumab in moderate to severe atopic dermatitis
According to JADE COMPARE trial data, the costs per responder of abrocitinib were considerably lower than dupilumab. The results of the study are limited to the short time frame of JADE COMPARE trial.
Authors
- Martina Maurelli (ORCID: https://orcid.org/0000-0001-7492-8010)
- Giampiero Girolomoni (ORCID: https://orcid.org/0000-0001-8548-0493)
- Paolo Gisondi (ORCID: https://orcid.org/0000-0002-1777-9001)
Institutions
- University of Verona (IT)
Publication Details
- Journal
- Italian Journal of Dermatology and Venereology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.23736/s2784-8671.24.07946-5
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.53